Related Experiment Videos
Treatment of hypercholesterolaemia with fenofibrate: a review
1Medlantic Research Foundation, Washington, D.C.
Insights
Fenofibrate effectively lowers high cholesterol and triglyceride levels, offering a safe treatment option for hypercholesterolaemia. This fibric acid derivative shows significant efficacy with a low incidence of adverse effects.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Hypercholesterolaemia is a metabolic disorder defined by elevated total and LDL-cholesterol.
- High cholesterol levels significantly increase the risk of coronary artery disease.
- Current guidelines advocate for the treatment of elevated cholesterol levels.
Purpose of the Study:
- To evaluate the efficacy and tolerability of fenofibrate for treating hypercholesterolaemia.
- To assess fenofibrate's impact on plasma lipid levels, including total cholesterol, LDL-cholesterol, and triglycerides.
- To review the safety profile and adverse effects associated with fenofibrate therapy.
Main Methods:
- Review of controlled and comparative clinical trials involving fenofibrate.
- Analysis of data on fenofibrate's effects on lipid profiles.
- Assessment of reported adverse events in clinical studies.
Main Results:
- Fenofibrate significantly reduces plasma levels of total cholesterol, LDL-cholesterol, and triglycerides.
- Clinical trials demonstrate fenofibrate's efficacy in managing dyslipidemia.
- Fenofibrate is associated with a low incidence of adverse effects, including gastrointestinal, dermatological, and musculoskeletal reactions.
Conclusions:
- Fenofibrate is an effective treatment for hypercholesterolaemia.
- The drug's favorable efficacy and tolerability profile make it suitable for selected patients.
- Fenofibrate represents an appropriate therapeutic choice for managing elevated cholesterol and triglyceride levels.
Abstract:
Hypercholesterolaemia is a metabolic disorder characterized by elevated total and LDL-cholesterol levels. Patients with hypercholesterolaemia are at high risk for coronary artery disease, and current guidelines recommend treatment for patients with elevated total or LDL-cholesterol levels. Fenofibrate is a fibric acid derivative that has been available in much of the world for over 10 years. In controlled and comparative clinical trials, fenofibrate has been shown to lower significantly plasma levels of total and LDL-cholesterol as well as plasma triglycerides. In addition, fenofibrate is associated with a relatively low incidence of adverse effects with some gastro-intestinal, dermatological and musculoskeletal reactions. Based on its efficacy and tolerability profile, fenofibrate would appear to be an appropriate choice for treatment of hypercholesterolaemia in selected patients.